Enhance your practice with CME and tools that focus on the management of neurological conditions.
Emerging Serum microRNAs as Early Signals in MS
Challenging the Status Quo in Schizophrenia Treatment
Shelina Ramnarine, PhD
Stephen Marder, MD
The Social Brain in Schizophrenia
Michael Green, PhD
Addressing Social and Systemic Barriers in Schizophrenia
Margaret Emerson, DNP, APRN, PMHNP-BC
Nutrition and the Gut-Brain Connection in Schizophrenia
Deanna L. Kelly, PharmD, BCPP
Treat. Target. Transform: Applying Treat-to-Target Principles in the Management of Generalized Myasthenia Gravis (gMG)
Christyn Edmundson, MD
Gil I. Wolfe MD, FAAN
Minimal By Design: Define MSE Endpoints
The IgG Clock: Redose Using IgG Kinetics
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
When to Begin FcRn: Initiation Criteria, Key Evidence
Escalate With Intention: Stepwise, Target-Anchored Moves
FcRn: Same Class, Different Paths—Spot Agent Differentiators
Updates in MS Care: Key Topics at AAN 2026
Aaron Miller, MD
Advancing Pediatric MS Care: Insights from AAN 2026
Elizabeth Wilson, MD
Strengthening Global Infrastructure for FSHD Trials
Marlene Mimi Maeusli, PhD.
The Burden of Cognitive Dysfunction in Multiple Sclerosis
Christopher Lock, MD
The 2-Point Signal: Apply ≥2-Point Rule
Family Planning in Patients with Multiple Sclerosis
Target Locked in gMG: Why T2T Matters
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Loading...
We're glad to see you're enjoying Global Neurology Academy… but how about a more personalized experience?
Press cancel to remain on Global Neurology Academy. Press the link below or the continue button to keep going.